The Indian market, live
Quality Power Q1 FY27 Revenue Up 32.1% to ₹2,564 Mn; Order Book at ₹19,455 Mn
Quality Power reported Q1 FY27 consolidated revenue of ₹2,564 million, up 32.1% YoY. Adjusted EBITDA rose 49.8% to ₹725 million, and adjusted PAT increased 47.2% to ₹545 million. The order book stands at ₹19,455 million. The company is proceeding with the acquisition of Winwin Speciality Insulators for ₹315 crore and declared an interim dividend of ₹0.25 per share.
Sky Gold Q1FY27: Revenue Surges 78% to ₹2,012.8 Crore, PAT Jumps 141% to ₹104.9 Crore
Sky Gold and Diamonds Limited reported Q1 FY27 revenue of ₹2,012.8 Crore, up 77.9% YoY. PAT surged 140.7% to ₹104.9 Crore. The company appointed Akash Talesara as CEO and highlighted plans for international expansion, including an initial order book of ₹30-45 Cr from the UK and Europe. New auditors, M S K A & Associates LLP, were appointed.
Sky Gold Q1 FY27 Revenue surges 78% YoY to ₹2,012.8 Cr, PAT up ~2.4x to ₹104.9 Cr
Sky Gold and Diamonds reported a strong Q1 FY27 with consolidated revenue up 78% YoY to ₹2,012.8 crore and PAT growing ~2.4x to ₹104.9 crore. EBITDA rose 119.6% to ₹156.7 crore. The company achieved positive operating cash flow and secured an export order book of ₹30-45 crore. Mr. Akash Talesara was appointed CEO.
Quality Power Approves Q1 FY27 Results, Declares Interim Dividend of ₹0.25, Expands Capacity
Quality Power reported strong Q1 FY27 results with an order book of ₹1,900 crore. The company declared an interim dividend of ₹0.25 per share, with a record date of August 14, 2026. Capacity expansion at Sangli and HVDC facilities is progressing. Mr. C. M. Shylendra Kumar was appointed CTO from August 17, 2026.
Gland Pharma inks Strategic CDMO Deal with Global Pharma Co.
Gland Pharma has signed a strategic Manufacturing and Supply Agreement with a global pharmaceutical company for sterile injectables. The deal includes technology transfer, manufacturing, and supply, with revenue expected from 2029. The annualized revenue potential is USD 90-100 million (approx. ₹750-₹830 crore) for 55 SKUs.
Gland Pharma inks CDMO deal with global co. for $90-100M revenue potential
Gland Pharma has signed a strategic Manufacturing and Supply Agreement (MSA) with a global pharmaceutical company for sterile injectables. The deal offers long-term business visibility, with revenue generation expected from CY2029. The partnership covers 55 SKUs across three sites, with an estimated annualized revenue potential of USD 90-100 million (₹750-830 crore).
Prism Johnson's 34th AGM: Shareholders Approve All Resolutions, Including Rs 500 Crore Fundraising
Prism Johnson Limited's 34th AGM on August 7, 2026, saw shareholders approve all resolutions. Key approvals include financial statements, director re-appointments, and a special resolution to raise up to ₹500 Crores via equity or convertible securities. Shareholder also approved private placement of non-convertible debentures.
Maruti Suzuki FY26 Sales Hit Record 24.22 Lakh Units; Plans 4 Biogas Plants
Maruti Suzuki reported record FY26 sales of 24.22 lakh vehicles and 4.47 lakh exports. The company plans to invest ₹561 crore in four biogas plants. It aims to introduce 7 SUVs in the next 5-6 years and added 500,000 manufacturing capacity in FY27.
Biocon Limited's 48th AGM: All resolutions passed, including dividend and new incentive plan.
Biocon Limited's 48th AGM on August 06, 2026, saw all resolutions passed. Key approvals include the final dividend of 10% (₹0.50/share), appointment of a new director, and adoption of the Biocon Unity Long Term Incentive Plan 2026. The company also approved financial assistance for employee stock plans.
Commercial Syn Bags Q1 FY27 Consolidated PAT Rises 61% to ₹893 Lakhs
Commercial Syn Bags reported Q1 FY27 consolidated PAT of ₹893.31 Lakhs, up 61% YoY. Standalone PAT rose 91% to ₹968.17 Lakhs. Revenue from operations increased to ₹10,912.57 Lakhs (Consolidated) and ₹10,830.19 Lakhs (Standalone). Commercial production commenced at the Techtex Unit on July 22, 2026.
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio - Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio - Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio
Summaries are generated from primary exchange filings and are for information only, not a recommendation to buy or sell. Also available as an RSS feed. For the live index overview and the Market Mood Index, see Markets; for model portfolios you can actually follow, see Discover.